2
Orphan Designations
0 approved, 2 designated
1
FDA Approvals
Latest: ZURNAI (2024)
0
Active Trials
2
Rare Diseases
across 7 areas
0
News (30d)
Quiet
Purdue Pharma L.P. is a company with 2 orphan drug designations across 2 rare diseases, including 1 FDA-approved therapy.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| T-cell prolymphocytic leukemia | tinostamustine hydrochloride | Des.TrialAppr. |
| malignant glioma | tinostamustine | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio